Osaka Soda Co., Ltd.

CONSOLIDATED FINANCIAL RESULTS For the quarterly period ended September 30, 2017 (Prepared under Japan GAAP, unaudited)

Company name: Osaka Soda Co.,Ltd. Stock Exchange Listing: Tokyo

Securities code: 4046 URL: http://www.osaka-soda.co.jp

Representative: Tamotsu Sato, Representative Director, Chief Executive Officer

For inquiry: Takuya Kajino, General Manager, Administration Division

(Telephone: +81-6-6110-1560)

Scheduled date of filing of quarterly report: November 8, 2017

Scheduled date of commencement of dividend payment: December 6, 2017 Supplementary materials prepared for the quarterly financial results: Yes

Quarterly financial results briefings: Yes (for institutional investors and investment analysts)

1. Consolidated Financial Results

(Amounts are rounded down to the nearest million yen)

(1) Results of Operations

	Six Months Ended			
	September 30, 2017		September 3	0, 2016
	Millions of yen Change *		Millions of yen	Change *
Net sales	47,989	4.5%	45,917	(8.8)%
Operating income	3,451	6.2%	3,248	5.5%
Ordinary income	3,809	46.5%	2,600	(20.1)%
Net income	2,494	41.4%	1,764	(10.8)%
Comprehensive income	4,154	251.8%	1,178	10.7%

Note: Percent changes for six months are year-on-year comparisons.

Net income per share (Yen)	118.00	83.73
Diluted net income per share (Yen)	95.42	69.48

Note: OSAKA SODA CO., LTD. (the "Company") will be completed common shares consolidation at the rate of 5 to 1, effective October 1, 2017. As a result, quarterly net income per share and quarterly diluted net income per share are calculated assuming that the share consolidation was executed at the beginning of the previous fiscal year.

(2) Financial Condition

	September 30, 2017		ptember 30, 2017 March 31, 2017	
	Millions of yen	en Ratio Millions of yen		Ratio
Total assets	116,281	_	101,503	_
Net assets	57,356	_	52,725	_
Equity	57,356	_	52,725	
Equity ratio	_	49.3%	_	51.9%

2. Dividends

	Year ending Mar. 31, 2018 (Forecast)	Year ending Mar. 31, 2018	Year ended Mar. 31, 2017
End of first quarter		_	_
End of second quarter		5.50	5.00
End of third quarter	_		_
End of fourth quarter	_		6.00
Full year	27.50		11.00

Note: The Company will be completed common shares consolidation at the rate of 5 to 1, effective October 1, 2017. As a result, the forecast of dividend per share for the fiscal year ending March 31, 2018 is effected by the share consolidation. Calculating annual dividend for the same fiscal year ending March 31, 2018 is not possible in accordance with the Ratio.

3. Earnings Forecast for the fiscal year ending March 31, 2018

	Full-year	
	Millions of yen Chang	
Net sales	100,000	6.9%
Operating income	7,000	6.3%
Ordinary income	7,000	7.1%
Net income	4,600	6.5%

Note: Percent changes are year-on-year comparisons.

Earnings per share (Yen)	218.32
--------------------------	--------

Note: The Company will be completed common shares consolidation at the rate of 5 to 1, effective October 1, 2017. As a result, the forecast of earnings per share for the fiscal year ending March 31, 2018 is effected by the share consolidation.

* Notes

- (1) Changes in significant subsidiaries during the period (Changes in specified subsidiaries resulting in the change in scope of consolidation): None
- (2) Application of accounting methods used specifically for the preparation of quarterly consolidated financial statements: None
- (3) Changes in accounting policies, accounting estimates and restatements of revisions
 - 1) Changes in accounting policies due to revisions of accounting standards, etc.: None
 - 2) Changes in accounting policies other than 1: None
 - 3) Changes in accounting estimates: None
 - 4) Restatement of revisions: None

(4) Number of outstanding shares (common stock)

1) Number of shares outstanding at the end of the period (including treasury shares)

As of September 30, 2017: 22,844,499 Shares As of March 31, 2017: 22,354,767 Shares

2) Number of treasury shares at the end of period

As of September 30, 2017: 1,286,580 Shares As of March 31, 2017: 1,285,645 Shares

3) Average number of shares outstanding in each period

Six months ended September 30, 2017: 21,139,395 Shares Six months ended September 30, 2016: 21,070,157 Shares

This quarterly financial results are not subject to the quarterly review procedure in accordance with the Financial Instruments and Exchange Act. The quarterly review procedure of consolidated financial statements has not been completed at the time of disclosure.

*Appropriate use of financial forecasts, other special notes

This material contains forward-looking statements such as earnings forecast about Osaka Soda Co., Ltd. and its group companies ("Osaka Soda Group"). These forward-looking statements are based on the current assumptions and beliefs of Osaka Soda Group in light of the information currently available to it, and contain known and unknown risks, uncertainties and other factors. Osaka Soda Group therefore wishes to caution readers that actual results could be materially different from any future results.

DISCLAIMER:

This is an English translation of the original Japanese document and is prepared for reference. Should there be any inconsistency between the translation and the Japanese original, the latter shall prevail.

^{*} Status of quarterly review procedure:

4. QUALITATIVE INFORMATION

(1)Results of Operations

During the six months ended September 30, 2017, Japan's economy has continued to recover moderately as a trend against the background of steady improvement in the corporate profit and employment situation, although the international situation has remained uncertain due to Trump administration's policy and geopolitical risks.

Basic Chemical Products

The cost competiveness has been strengthened by building an efficient production system. And the sales price increases have been implemented, affecting the change of raw material and fuel cost.

Functional Chemical Products

The sales activities have been accelerated to expand market share in synthetic rubber and synthetic resins that are our core products, and we focused on the early launch of new products such as acrylic rubber.

We are cultivating the healthcare related business as a third pillar of profit. The contract manufacturing projects using special equipment have been acquired and the new business has been created in the field of active pharmaceutical ingredients and their intermediates. The new customers in Eastern Europe, China, and India have been developed in the purification of pharmaceutical products. As of August 2017, we have agreed to be transferred chromatography business from Shiseido Company, Limited. Accordingly, the integrated production system will be completed in the field of drugs purification in December 2017.

Housing Facilities and Others

The profitability has been strengthened by continuing to change the business portfolio.

As a result, net sales were ¥47,989 million, an increase of 4.5% compared to the same period of fiscal 2016. Operating income was ¥3,451 million, an increase of 6.2% compared to the same period of fiscal 2016. Ordinary income was ¥3,809 million, an increase of 46.5% compared to the same period of fiscal 2016. Net income attributable to owners of parent was ¥2,494 million, an increase of 41.4% compared to the same period of fiscal 2016.

Basic Chemical Products

In *Chlor-Alkali*, net sales increased due to continued steady shipments in caustic soda as well as implementation of sales price increase. .

In *Epichlorhydrin*, net sales increased due to steady sales volume affecting overseas market conditions by improvement of supply-demand in Asia.

As a result, net sales in Basic Chemical Products were ¥21,391 million, an increase of 7.5% compared to the same period of fiscal 2016.

Functional Chemical Products

In *Epichlorhydrin Rubber*, net sales increased due to recovery in domestic demand and steady increase in shipment of automobile to Europe and China. And we enhanced sales activities in acrylic rubber.

In *Diallyl Phthalate Resin*, net sales increased due to continued favorable export sales, backed by sales expansion of high sensitivity UV inks to Europe and success in pioneering new application.

In Allyl Ethers, net sales increased due to continued steady export sales to USA and China mainly applied for silane coupling agents.

In Active Pharmaceutical Ingredients and their Intermediates, net sales increased due to continued favorable domestic sales in "Anti-viral drugs", "Treatment of insomnia" and "Ingredients of cosmeceuticals" as well as overseas sales in "Active pharmaceutical Ingredients of cardiotonic drug" and imported sales in generic drug substance.

In Separation Media in Pharmaceutical Industry (Silica Gel for Liquid Chromatography), net sales increased

due to continued steady sales to China applied for biopharmaceutical purification and domestic market, despite inventory adjustments by European major customers, and continued steady sales applied for analytical and purification of active pharmaceutical ingredients.

As a result, net sales in Functional Chemical Products were ¥19,437 million, an increase of 6.1% compared to the same period of fiscal 2016.

Housing Facilities and Others

Net sales in housing facilities and others were ¥7,159 million, a decrease of 7.0% compared to the same period of fiscal 2016.

(2) Financial Condition

Assets

Current assets were ¥70,874 million, a decrease of 20.7% since March 31, 2017. The increase was due primarily to an increase of ¥9,999 million in *short term investment securities*, an increase of ¥196 million in *notes and accounts receivable-trade*, an increase of ¥438 million in *electrically recorded monetary claims*.

Noncurrent assets were ¥45,406 million, an increase of 6.2% since March 31, 2017. The increase was due primarily to an increase of ¥2,303 million in *investment securities*.

As a result, *Total assets* were ¥116,281 million as of September 30, 2017, an increase of 14.6% since March 31, 2017.

Liabilities

Current liabilities were ¥32,830 million, an increase of 4.6% since March 31, 2017. The increase was due primarily to an increase of ¥2,020 million in *notes and accounts payable-trade*.

Noncurrent liabilities were ¥26,094million, an increase of 50.1% since March 31, 2017. The decrease was due primarily to an increase of ¥8,879 million in *bonds with subscription rights to shares*.

As a result, *Total liabilities* were ¥58,924 million as of September 30, 2017, an increase of 20.8% since March 31, 2017.

Net assets

Net assets were ¥57,356 million as of September 30, 2017, an increase of 8.8% since March 31, 2017.

(3) Cash Flows

As of September 30, 2017, cash and cash equivalents were ¥30,321 million, an increase of ¥9,778 million compared with those as of March 31, 2017.

Cash flows from operating activities

Net cash provided by operating activities totaled ¥3,853 million, due primarily to ¥3,620 million in *income* before income taxes and ¥1,542 million in depreciation, a decrease of ¥1,162 million in income tax paid.

Cash flows from investing activities

Net cash used in investing activities totaled ¥2,306 million, due primarily to payments of ¥2,161 million for purchase of *property, plant, and equipment*.

Cash flows from financing activities

Net cash used in financing activities amounted to ¥8,044 million, due primarily to proceeds of ¥9,967 million from the issuance of convertible bond-type bonds with subscription rights.

(4) Earnings Forecast

There are no revisions to the earnings forecast from the previous forecast announced in the "Consolidated financial results for the year ended March 31, 2018" dated May 9, 2017.

5. CONSOLIDATED FINANCIAL STATEMENTS

CONSOLIDATED BALANCE SHEETS

	March 31, 2017	September 30, 2017
Assets		
Current assets		
Cash and deposits	11,033	10,882
Notes and accounts receivable-trade	25,397	27,357
Electrically recorded monetary claims	2,497	2,936
Short term investment securities	9,499	19,499
Merchandise and finished goods	5,743	6,059
Work in process	1,411	1,577
Raw materials and supplies	1,667	1,472
Other current assets	1,491	1,152
Less: Allowance for doubtful accounts	(3)	(3)
Total current assets	58,739	70,874
Noncurrent assets		
Property, plant, and equipment		
Property, plant, and equipment - Net	11,339	10,425
Other - Net	10,216	11,662
Total property, plant and equipment	21,555	20,088
Intangible assets		
Goodwill	769	716
Other	437	502
Total intangible assets	1,207	1,218
Investments and other assets		
Investment securities	18,927	21,260
Other	1,641	1,405
Less: Allowance for doubtful accounts	(568)	(566)
Total investment and other assets	20,001	22,099
Total noncurrent assets	42,764	45,406
Total assets	101,503	116,281

CONSOLIDATED BALANCE SHEETS (Continued)

	March 31,	September 30,
-	2017	2017
Liabilities		
Current liabilities		
Notes and accounts payable- trade	13,339	15,359
Short term loans payable	8,880	8,880
Current portion of long term loans payable	2,160	1,760
Income taxes payable	1,311	1,165
Provision for bonuses	712	757
Other current liabilities	4,987	4,907
Total current liabilities	31,390	32,830
Noncurrent liabilities		
Bonds with subscription rights to shares	9,999	18,878
Long term loans payable	800	_
Provision for directors retirement benefits	567	572
Net defined benefit liability	2,927	2,916
Other noncurrent liabilities	3,093	3,726
Total noncurrent liabilities	17,387	26,094
Total liabilities	48,778	58,924
Net assets		
Shareholders' equity		
Capital stock	10,882	11,443
Capital surplus	9,399	9,960
Retained earnings	27,964	29,826
Treasury stock	(1,670)	(1,673)
Total shareholders' equity	46,576	49,556
Accumulated other comprehensive income	<u> </u>	·
Unrealized gain on available-for-sale securities	6,481	8,092
Deferred gains or losses on hedges	(13)	6
Foreign currency translation adjustments	24	21
Re-measurements of defined benefit plans	(342)	(320)
Total accumulated other comprehensive income	6,149	7,799
Total net assets	52,725	57,356
Total net assets and liabilities	101,503	116,281
-	,	,

CONSOLIDATED STATEMENTS OF INCOME

Net sales 45,917 47,989 Cost of sales 36,837 38,682 Gross profit 9,079 9,306 Selling, general, and administrative expenses 5,831 5,855 Operating income 3,248 3,451 Non-operating income 15 7 Dividend income 193 212 Foreign exchange gain - 220 Other 41 45 Total non-operating income 250 485 Non-operating expenses 34 68 Bond issuance cost - 32 Foreign exchange loss 845 - Other 18 25 Foreign exchange loss 845 - Other 18 25 Total non-operating expenses 898 127 Otdiary income 2,600 3,809 Extraordinary income - 106 Gain on sales of investment securities - 106 Total extraordinary income - 10		Six Months Ended	
Net sales 45,917 47,989 Cost of sales 36,837 38,682 Gross profit 9,079 9,306 Selling, general, and administrative expenses 5,831 5,855 Operating income 3,248 3,451 Non-operating income 15 7 Dividend income 193 212 Foreign exchange gain - 220 Other 41 45 Total non-operating income 250 485 Non-operating expenses 34 68 Bond issuance cost - 32 Foreign exchange loss 845 - Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income - 106 Gain on sales of investment securities - 106		September 30,	September 30,
Cost of sales 36,837 38,682 Gross profit 9,079 9,306 Selling, general, and administrative expenses 5,831 5,855 Operating income 3,248 3,451 Non-operating income 15 7 Dividend income 193 212 Foreign exchange gain - 220 Other 41 45 Total non-operating income 250 485 Non-operating expenses 34 68 Bond issuance cost - 32 Foreign exchange loss 845 - Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income - 106 Gain on sales of investment securities - 106		2016	2017
Gross profit 9,079 9,306 Selling, general, and administrative expenses 5,831 5,855 Operating income 3,248 3,451 Non-operating income 15 7 Interest income 15 7 Dividend income 193 212 Foreign exchange gain - 220 Other 41 45 Total non-operating income 250 485 Non-operating expenses 34 68 Bond issuance cost - 32 Foreign exchange loss 845 - Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income - 106 Gain on sales of investment securities - 106	Net sales	45,917	47,989
Selling, general, and administrative expenses 5,831 5,855 Operating income 3,248 3,451 Non-operating income 15 7 Interest income 193 212 Foreign exchange gain - 220 Other 41 45 Total non-operating income 250 485 Non-operating expenses 34 68 Bond issuance cost - 32 Foreign exchange loss 845 - Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income - 106 Gain on sales of investment securities - 106	Cost of sales	36,837	38,682
Operating income 3,248 3,451 Non-operating income 15 7 Interest income 193 212 Foreign exchange gain — 220 Other 41 45 Total non-operating income 250 485 Non-operating expenses 34 68 Bond issuance cost — 32 Foreign exchange loss 845 — Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income — 106 Gain on sales of investment securities — 106	Gross profit	9,079	9,306
Non-operating income Interest income 15 7 Dividend income 193 212 Foreign exchange gain — 220 Other 41 45 Total non-operating income 250 485 Non-operating expenses 34 68 Bond issuance cost — 32 Foreign exchange loss 845 — Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income — 106 Gain on sales of investment securities — 106	Selling, general, and administrative expenses	5,831	5,855
Interest income 15 7 Dividend income 193 212 Foreign exchange gain — 220 Other 41 45 Total non-operating income 250 485 Non-operating expenses 34 68 Bond issuance cost — 32 Foreign exchange loss 845 — Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income — 106 Gain on sales of investment securities — 106	Operating income	3,248	3,451
Dividend income 193 212 Foreign exchange gain — 220 Other 41 45 Total non-operating income 250 485 Non-operating expenses 34 68 Bond issuance cost — 32 Foreign exchange loss 845 — Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income — 106 Gain on sales of investment securities — 106	Non-operating income		
Foreign exchange gain — 220 Other 41 45 Total non-operating income 250 485 Non-operating expenses 34 68 Bond issuance cost — 32 Foreign exchange loss 845 — Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income — 106	Interest income	15	7
Other 41 45 Total non-operating income 250 485 Non-operating expenses 34 68 Interest expenses 34 68 Bond issuance cost - 32 Foreign exchange loss 845 - Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income - 106 Gain on sales of investment securities - 106	Dividend income	193	212
Total non-operating income 250 485 Non-operating expenses 34 68 Interest expenses 34 68 Bond issuance cost — 32 Foreign exchange loss 845 — Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income — 106 Gain on sales of investment securities — 106	Foreign exchange gain	_	220
Non-operating expenses Interest expenses 34 68 Bond issuance cost — 32 Foreign exchange loss 845 — Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income — 106	Other	41	45
Interest expenses 34 68 Bond issuance cost — 32 Foreign exchange loss 845 — Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income — 106 Gain on sales of investment securities — 106	Total non-operating income	250	485
Bond issuance cost — 32 Foreign exchange loss 845 — Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income — 106 Gain on sales of investment securities — 106	Non-operating expenses		
Foreign exchange loss 845 — Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income — 106 Gain on sales of investment securities — 106	Interest expenses	34	68
Other 18 25 Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income - 106 Gain on sales of investment securities - 106	Bond issuance cost	_	32
Total non-operating expenses 898 127 Ordinary income 2,600 3,809 Extraordinary income Gain on sales of investment securities — 106	Foreign exchange loss	845	_
Ordinary income2,6003,809Extraordinary income3,809Gain on sales of investment securities—106	Other	18_	25
Extraordinary income Gain on sales of investment securities	Total non-operating expenses	898	127
Gain on sales of investment securities 106	Ordinary income	2,600	3,809
	Extraordinary income		
Total extraordinary income	Gain on sales of investment securities		106
	Total extraordinary income	_	106
Extraordinary loss	Extraordinary loss		
Loss on retirement of noncurrent assets 262 295	Loss on retirement of noncurrent assets	262	295
Total extraordinary loss	Total extraordinary loss	262	295
Income before income taxes 2,338 3,620	Income before income taxes	2,338	3,620
Income taxes - current 673 1,027	Income taxes - current	673	1,027
Income taxes - deferred (100) 98	Income taxes - deferred	(100)	98
Total income taxes 573 1,125	Total income taxes	573	1,125
Net income 1,764 2,494	Net income	1,764	2,494
Net income attributable to non-controlling interests	Net income attributable to non-controlling interests		
Net income attributable to owners of parent 1,764 2,494	Net income attributable to owners of parent	1,764	2,494

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

	Six Months Ended		
	September 30,	September 30,	
	2016	2017	
Net income	1,764	2,494	
Other comprehensive income			
Unrealized gain on available-for-sale securities	(605)	1,611	
Deferred gains or losses on hedges	40	19	
Foreign currency translation adjustments	(51)	(3)	
Re-measurements of defined benefit plans	29	22	
Total	(586)	(1,650)	
Comprehensive income	1,178	4,145	
Comprehensive income attributable to:			
Owners of parent	1,178	4,145	
Minority interests	_	_	

CONSOLIDATED STATEMENTS OF CHASH FLOWS

	Six Months Ended	
	September 30,	September 30,
	2016	2017
Cash flows from operating activities		
Income (loss) before income taxes	2,338	3,620
Depreciation	1,440	1,542
Amortization of goodwill	77	77
Increase (decrease) in allowance for doubtful accounts	(13)	(1)
Increase (decrease) in provision for bonuses	15	44
Increase (decrease) in provision for directors' retirement	(3)	5
benefits		
Increase (decrease) in allowance for retirement benefits for	1	(10)
employees		
Interest and dividend income	(208)	(219)
Interest expenses	34	68
Foreign exchange losses (gains)	678	(193)
Loss on retirement of non-current assets	262	295
Loss (gain) on sales of non-current assets	_	(106)
Bond issuance cost	_	32
Decrease (increase) in notes and accounts receivable-trade	934	(2,390)
Decrease (increase) in inventories	552	(282)
Increase (decrease) in notes and accounts payable-trade	210	2,003
Other, net	(98)	373
Subtotal	6,220	4,859
Interest and dividend income received	208	219
Interest expenses paid	(35)	(63)
Income taxes paid	(1,254)	(1,162)
Net cash provided by (used in) operating activities	5,138	3,853

CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)

	Six Months Ended	
	September 30,	September 30,
_	2016	2017
Cash flows from investing activities	_	
Purchase of property, plant and equipment	(1,175)	(2,161)
Proceeds from sales of property, plant and equipment	_	115
Purchase of intangible assets	(97)	(178)
Purchase of investment securities	(252)	(9)
Other, net	(244)	(72)
Net cash provided by (used in) investing activities	(1,769)	(2,306)
Cash flows from financing activities		
Repayments of long-term loans payable	(1,220)	(1,200)
Proceeds from issuance of bonds with subscription rights	_	9,967
to shares		
Cash dividends paid	(525)	(631)
Other, net	(1)	(90)
Net cash provided by (used in) financing activities	(1,747)	8,044
Effect of exchange rate change on cash and cash	(745)	196
equivalents		
Net increase (decrease) in cash and cash equivalents	876	9,788
Cash and cash equivalents	19,036	20,532
Cash and cash equivalents	19,912	30,321

6. Notes to the Consolidated Financial Statements

- (1) Notes regarding the going concern assumption None
- (2) Notes regarding significant changes in the amount of shareholders' equity None

(3) Segment information

Six months ended September 30, 2016

(Millions of yen)

	Net sales			Sogmont
	External	Intersegment sales	Total	Segment income
	sales	or reclassifications		
Basic Chemical Products	19,902	9	19,912	498
Functional Chemical Products	18,313	0	18,314	3,163
Housing Facilities and Others	7,700	694	8,395	55
Total	45,917	704	46,622	3,717
Adjustments *1	_	(704)	(704)	(468)
Consolidated operating income *2	45,917	_	45,917	3,248

Notes 1: Adjustments of segment income of ¥(468) million are corporate expenses not allocated to reportable segments. Corporate expenses are mainly expenses not attributable to a reporting segment and related to fundamental research and development as well as administrative departments.

Notes 2: Segment Income is reconciled with consolidated operating income.

Six months ended September 30, 2017

(Millions of yen)

	Net sales			Sogmont
	External	Intersegment sales	Total	Segment income
	sales	or reclassifications		income
Basic Chemical Products	21,391	4	21,396	986
Functional Chemical Products	19,437	10	19,448	2,900
Housing Facilities and Others	7,159	606	7,766	43
Total	47,989	621	48,611	3,929
Adjustments *1	_	(621)	(621)	(478)
Consolidated operating income *2	47,989		47,989	3,451

Notes 1: Adjustments of segment income of ¥(478) million are corporate expenses not allocated to reportable segments. Corporate expenses are mainly expenses not attributable to a reporting segment and related to fundamental research and development as well as administrative departments.

Notes 2: Segment Income is reconciled with consolidated operating income.